Anti-CTLA-4 therapy for malignant mesothelioma

Guazzelli, A; Bakker, EY; Krstic-Demonacos, M; Lisanti, MP; Sotgia, F; Mutti, L

Abstract

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This special report aims to describe the state of clinical trials of tremelimumab in patients with unresectable malignant mesothelioma (MM) in particular with regard to the clinical efficacy, safety and tolerability. Criticism and perspective of this treatment are also discussed. Biological and clinical considerations rule out the use of tremelimumab as single agent for MM and, more generally, the use of immune checkpoint inhibitors for MM is still largely questionable and not supported by evidences.

Citation

Guazzelli, A., Bakker, E., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy, 9(3), 273-280. https://doi.org/10.2217/imt-2016-0123

• Journal Article Type: Article
• Online Publication Date: Feb 24, 2017
• Publication Date: Mar 1, 2017
• Deposit Date: Jun 6, 2017
• Publicly Available Date: May 1, 2018
• Journal: Immunotherapy
• Print ISSN: 1750-743X
• Publisher: Future Medicine
• Volume: 9
• Issue: 3
• Pages: 273-280
• DOI: https://doi.org/10.2217/imt-2016-0123
• Publisher URL: https://doi.org/10.2217/imt-2016-0123
• Related Public URLs: http://www.futuremedicine.com/loi/imt